- Home
- CGBD vs IMTX Comparison
CGBD vs IMTX Comparison
Compare CGBD & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- IMTX
- Stock Information
- Founded
- CGBD 2012
- IMTX N/A
- Country
- CGBD United States
- IMTX Germany
- Employees
- CGBD N/A
- IMTX N/A
- Industry
- CGBD Finance: Consumer Services
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGBD Finance
- IMTX Health Care
- Exchange
- CGBD Nasdaq
- IMTX Nasdaq
- Market Cap
- CGBD 881.7M
- IMTX 954.2M
- IPO Year
- CGBD 2017
- IMTX N/A
- Fundamental
- Price
- CGBD $18.00
- IMTX $6.85
- Analyst Decision
- CGBD Hold
- IMTX Strong Buy
- Analyst Count
- CGBD 4
- IMTX 4
- Target Price
- CGBD $16.25
- IMTX $16.67
- AVG Volume (30 Days)
- CGBD 228.5K
- IMTX 516.6K
- Earning Date
- CGBD 11-05-2024
- IMTX 11-18-2024
- Dividend Yield
- CGBD 2.67%
- IMTX N/A
- EPS Growth
- CGBD 29.39
- IMTX N/A
- EPS
- CGBD 1.72
- IMTX N/A
- Revenue
- CGBD $238,921,000.00
- IMTX $128,824,447.00
- Revenue This Year
- CGBD N/A
- IMTX $120.90
- Revenue Next Year
- CGBD $4.63
- IMTX N/A
- P/E Ratio
- CGBD $10.44
- IMTX N/A
- Revenue Growth
- CGBD 1.68
- IMTX 52.53
- 52 Week Low
- CGBD $14.76
- IMTX $6.68
- 52 Week High
- CGBD $18.74
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- CGBD 65.73
- IMTX 27.51
- Support Level
- CGBD $17.61
- IMTX $6.68
- Resistance Level
- CGBD $18.19
- IMTX $7.40
- Average True Range (ATR)
- CGBD 0.32
- IMTX 0.33
- MACD
- CGBD 0.04
- IMTX -0.03
- Stochastic Oscillator
- CGBD 72.03
- IMTX 10.43
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.